Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Retained Earnings (2022 - 2025)

NewAmsterdam Pharma's Retained Earnings history spans 4 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.86% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, up 100.86%, while the annual FY2025 figure was $4.8 million, 100.86% up from the prior year.
  • Retained Earnings for Q4 2025 was $4.8 million at NewAmsterdam Pharma, up from -$687.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $4.8 million in Q4 2025 and bottomed at -$687.5 million in Q3 2025.
  • The 4-year median for Retained Earnings is -$430.2 million (2024), against an average of -$329.7 million.
  • The largest annual shift saw Retained Earnings skyrocketed 103.63% in 2023 before it crashed 12731.64% in 2024.
  • A 4-year view of Retained Earnings shows it stood at -$121.8 million in 2022, then soared by 103.63% to $4.4 million in 2023, then plummeted by 12731.64% to -$558.6 million in 2024, then soared by 100.86% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Retained Earnings are $4.8 million (Q4 2025), -$687.5 million (Q3 2025), and -$615.5 million (Q2 2025).